However, recently CD19-CAR-Ts were proven to be highly efficient in the treatment of autoimmune diseases, including systemic lupus erythematosus, idiopathic inflammatory myositis, and systemic sclerosis, by elimination of autoantibody-releasing B cells, although they were shown not to deplete long-lived plasma cells.22 Here, CD19 is linked to acquired idiopathic inflammatory myopathy.